APR 20, 2019 10:39 PM PDT

The Microfluidic-Based Drug Screening Chip

WRITTEN BY: Nouran Amin

A team of researchers, at the Korea Advanced Institute of Science and Technology (KAIST), created a high throughput microfluidic-based drug screening chip that works to identify interactions between two antibiotics in eight hours. The screening chip can generate 121 pairwise concentrations and serve as a cell-based drug screening platform for surveying critical pharmacological patterns from these antibiotic interactions. The screening application can also be crucial for other cell-type agents and for use in clinical therapies.

Back cover image for the "Lab on a Chip". Credit: The Korea Advanced Institute of Science and Technology (KAIST)

Current antibiotic susceptibility testing determines different types and doses of antibiotics that can block the growth of bacteria. Such testing has become critical with the rise of antibiotic resistance.

Overcoming antibiotic-resistant bacteria involves combination therapy of two or more kinds of antibiotics but, this kind of therapy is not always effective with the occasional unfavorable antibiotic pairs that result to suppressed antimicrobial effects.

The microfluidic-based drug screening chip will reduce time and enhance the efficiency of the combinatory testing. Using a sample volume of a few tens of microliters, the chip enabled 121 pairwise concentrations of two antibiotics to be formed in only 35 minutes.

Researchers used a mixture of bacteria and agarose and inserted into a microchannel. The mixture included injected reagents with or without antibiotics into the surrounding microchannel. The channel that had antibiotic molecules diffused into the channel without antibiotics and resulted in the formation of two orthogonal concentration gradients on the bacteria-trapping agarose gel.

Examples of testing results using the microfluidic chips developed in this research. Credit: The Korea Advanced Institute of Science and Technology (KAIST)

Over a course of six hours, researchers were successful in microscopically observing the inhibition of bacterial growth by the antibiotic orthogonal gradients. The observations confirmed the different patterns of antibiotic pairs along with the different interaction types into either synergy or antagonism.

"The feasibility of microfluidic-based drug screening chips is promising, and we expect our microfluidic chip to be commercialized and utilized in near future,” says Professor Jessie Sungyun Jeon from the Department of Mechanical Engineering at KAIST.

Source: Phys.org

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
DEC 05, 2019
Drug Discovery & Development
DEC 05, 2019
AI Exponentially Accelerates Drug Development
Research and development for new drugs is both an expensive and lengthy process, often lasting years, if not decades. With the development of artificial in...
DEC 05, 2019
Genetics & Genomics
DEC 05, 2019
Breast Cancer Drug Increases Survival for Prostate Cancer Patients
A breast cancer drug is better at treating advanced prostate cancer in some men than current therapies, a clinical trial shows....
DEC 05, 2019
Cannabis Sciences
DEC 05, 2019
CBD Extract for Cannabis Addiction
Some people believe the secret to curing a hangover is to drink more alcohol the morning after a night of binge drinking - “the hair of the dog that...
DEC 05, 2019
Drug Discovery & Development
DEC 05, 2019
Investigating a common therapeutic in ADHD treatment
Attention-Deficit Hyperactivity Disorder (ADHD) is a widespread condition with variable underlying causes. A common therapeutic, called methylphenidate, se...
DEC 05, 2019
Neuroscience
DEC 05, 2019
The Women Who Can Smell Without Olfactory Bulbs
Until now, it has been commonly accepted that our sense of smell depends on the transmission of olfactory information from the nose to the olfactory bulb i...
DEC 05, 2019
Drug Discovery & Development
DEC 05, 2019
FDA Approves New Drug for Sickle Cell Disease
Sickle cell disease affects approximately 100,000 Americans. Currently, the only available cure for the disease is a costly bone marrow transplant, putting...
Loading Comments...